ALLOPURINOL-200 200 MG — DIN 02130157
ALLOPURINOL : 200 MG · PRO DOC LIMITEE · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is ALLOPURINOL-200?
ALLOPURINOL-200 200 MG contains ALLOPURINOL : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02130157, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALLOPURINOL-200 used for?
Treatment of gout; primary/secondary uric acid nephropathy; prophylaxis of urate deposition/renal calculi in malignancies; prevention of uric acid stones and renal calcium lithiasis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Allopurinol cost around the world?
Allopurinol is listed on 16 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 3 | 83 | USD███.██ |
| Australia | ex-manufacturer | 9 | 30 | AUD███.██ |
| South Africa | single exit price | 18 | 28 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 15 | 20 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 18 | SEK███.██ |
| Czechia | max producer price (ex-factory) | 4 | 14 | CZK███.██ |
| Saudi Arabia | public | 11 | 12 | SAR███.██ |
| Morocco | PPV (public price) | 3 | 11 | MAD███.██ |
| Norway | max AUP (pharmacy retail) | 4 | 9 | NOK███.██ |
| United Arab Emirates | public | 6 | 7 | AED███.██ |
| Bahrain | retail (max) | 4 | 7 | BHD███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
259 pack listings across 103 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every Allopurinol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Allopurinol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Allopurinol, across 51 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 7 | 3 | ALLOPURINOL, APO-ALLOPURINOL, APO-ALLOPURINOL TABLETS | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 6 | 3 | JAMP ALLOPURINOL, JAMP ALLOPURINOL TABLETS | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 6 | 3 | IPG-ALLOPURINOL, MAR-ALLOPURINOL | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | ALLOPURINOL-100, ALLOPURINOL-200, ALLOPURINOL-300 | Sourceable in Canada |
| ANGITA PHARMA INC. | 3 | 0 | AG-ALLOPURINOL | No marketed DIN |
| CARTER-HORNER CORP. | 3 | 0 | PURINOL TAB 100MG, PURINOL TAB 200MG, PURINOL TAB 300MG | No marketed DIN |
| LABORATOIRES CONFAB INC | 3 | 0 | ALLOPURINOL TABLETS 100MG, ALLOPURINOL TABLETS 200MG, ALLOPURINOL TABLETS 300MG | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-PUROL TAB 100MG, NOVO-PUROL TAB 200 MG, NOVO-PUROL TAB 300MG | No marketed DIN |
| NU-PHARM INC | 3 | 0 | NU-ALLOPURINOL | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-ALLOPURINOL | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | NTP-ALLOPURINOL | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 3 | 0 | ALLOPRIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 100 mg: Bottles of 100 and 1000. 200 mg & 300 mg: Bottles of 100 and 500. |
| Storage | Not explicitly specified in provided text (standard section 11 header present but details cut off). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Allopurinol |
|---|---|
| ATC code | M04AA01 |
| AHFS class | 28:16.04.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02130157 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2130157 |
| Brand name | ALLOPURINOL-200 |
| Generic / active ingredient | ALLOPURINOL : 200 MG |
| Market authorization holder | PRO DOC LIMITEE |
| Health Canada schedule | Prescription |
| ATC code | M04AA01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M04AA |
| Current status | MARKETED |
| Status date | 28-Nov-2013 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 100-800 mg/day based on severity. Doses >300 mg should be divided. Take after meals. Maintain fluid intake for 2L/day urinary output.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to allopurinol; breast-feeding women; children (except for secondary hyperuricemia in malignancy or Lesch-Nyhan syndrome).
Warnings and precautions
Discontinue immediately at first sign of rash (risk of SJS/TEN/DRESS). HLA-B*5801 allele increases risk. May cause drowsiness. Monitor thyroid, renal, and hepatic function.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 51 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALLOPURINOL-100 | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00555681 |
| ALLOPURINOL-300 | 300 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00555703 |
| APO-ALLOPURINOL TABLETS | 100 MG | TABLET | APOTEX INC | MARKETED | 00402818 |
| APO-ALLOPURINOL TABLETS | 300 MG | TABLET | APOTEX INC | MARKETED | 00402796 |
| APO-ALLOPURINOL TABLETS | 200 MG | TABLET | APOTEX INC | MARKETED | 00479799 |
| JAMP ALLOPURINOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02421593 |
| JAMP ALLOPURINOL | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02421615 |
| JAMP ALLOPURINOL | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02421607 |
| MAR-ALLOPURINOL | 200 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02396335 |
| MAR-ALLOPURINOL | 100 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02396327 |
2 · Same class — other molecules in ATC M04AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Allopurinol | AG-ALLOPURINOL · ALLOPRIN · ALLOPURINOL · ALLOPURINOL TABLETS 100MG · +25 more | 51 | 12 | Yes |
| Febuxostat | AURO-FEBUXOSTAT · FEBUXOSTAT · JAMP FEBUXOSTAT · M-FEBUXOSTAT · +3 more | 7 | 6 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M04AC | Colchicine | 10 | 3 |
| M04AB | Probenecid · Sulfinpyrazone | 16 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ALLOPURINOL-200 called?
The same molecule, Allopurinol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zyloric | Latin | Bahrain, Morocco, Norway, Saudi Arabia |
| Allopurinol Sandoz | Latin | Australia, Norway, Sweden |
| MILURIT | Latin | Czechia |
| Zyloprim | Latin | Australia, South Africa |
| PURINOL | Latin | Czechia, Morocco |
| Allopurinol Nordic Drugs | Latin | Sweden |
| Allopurinol Orifarm | Latin | Sweden |
| Allopurinol Orion | Latin | Norway, Sweden |
| ALLOPURINOL-WGR | Latin | Australia |
| Allosig | Latin | Australia |
| APO-ALLOPURINOL | Latin | Australia |
| Progout Viatris | Latin | Australia |
| Puricos | Latin | South Africa |
| ALOPURINOL SANDOZ | Latin | Czechia |
| Redurate | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.